Loading stock data…
$5.25+0.12 (+2.34%)
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs.
PolyPid Ltd. in the Healthcare sector is trading at $5.25 with a market capitalization of $105M. Wall Street consensus targets $11.75 (4 analysts), implying a +123.8% move over the next 12 months. The stock is currently 8% below its 52-week high of $5.73, remaining 11.7% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$7.85M↓ | -$7.76M↑ | -$8.53M↓ | -$7.46M↑ | -$9.40M |
| Net Income | -$7.85M↓ | -$7.73M↑ | -$8.47M↓ | -$7.45M↑ | -$9.98M |
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candi...